Orthofix Cuts 2026 Guidance on Weak U.S. Spine; Q3 Sales $207.9M, EBITDA $26.0M
OFIX is trading near its 52-week low of $7.81 (15% below the low) on elevated volume (2.0× avg).
Summary
Orthofix reported Q3 2026 sales of $207.9M and adjusted EBITDA of $26.0M, then cut full-year 2026 guidance to $825M-$830M in sales and $86M-$88M in adjusted EBITDA on weaker U.S. Spine performance.
Key Events · Earnings and Guidance · OFIX
-
2026 Guidance Cut on Spine Weakness
Full-year 2026 net sales guidance was lowered to $825M-$830M from $845M-$855M, and adjusted EBITDA to $86M-$88M from $95M-$98M, reflecting Q3 performance, continued Spine market softness, supplier delays and instrument-set constraints.
-
Q3 Sales $207.9M, EBITDA $26.0M
Reported net sales rose 1.1% to $207.9M (2.3% pro forma constant currency), and adjusted EBITDA was $26.0M, or 12.5% of pro forma net sales, versus $24.6M a year earlier. Net loss narrowed to $(6.1)M, or $(0.15) per share, from $(22.8)M.
-
Segment Split: Limb Recon Up, Spine Down
Global Limb Reconstruction grew 9.4% constant currency to $36.4M and Therapeutic Solutions rose 4.5% to $64.0M, while Spinal Implants, Biologics and Enabling Technologies fell 1.1% to $107.4M; U.S. Spine declined 4.3%.
-
Cash and Free Cash Flow Pressure
Cash, cash equivalents and restricted cash totaled $86.9M at September 30, 2026, down from $104.4M at June 30, 2026; nine-month free cash flow was $(61.3)M versus $(18.1)M a year ago.
Analysis · OFIX · Industrial Applications And Services
Orthofix lowered full-year 2026 net sales guidance to $825M-$830M from $845M-$855M and adjusted EBITDA to $86M-$88M from $95M-$98M, citing continued Spine market softness, unplanned supplier delays, instrument-set constraints and the cost of accelerated U.S. Spine fixes. That removes roughly $20M-$25M of revenue and $9M-$10M of EBITDA from the year, and it lands while the stock trades near its 52-week low. The quarter itself was not a collapse: sales rose 2.3% pro forma constant currency, and adjusted EBITDA of $26.0M was actually up from $24.6M a year ago. But the cut tells investors the Spine problem is getting worse before it gets better. Cash fell to $86.9M from $104.4M sequentially, and nine-month free cash flow was negative $61.3M, so the runway to positive cash flow now depends on execution the company has not yet demonstrated.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OFIX was trading at $6.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $320.6M. The 52-week trading range was $7.81 to $16.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.